FY2024 EPS Estimates for Personalis Lowered by HC Wainwright

Personalis, Inc. (NASDAQ:PSNL - Free Report) - Equities research analysts at HC Wainwright lowered their FY2024 EPS estimates for Personalis in a report released on Monday, January 27th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($1.36) per share for the year, down from their prior forecast of ($1.29). HC Wainwright has a "Buy" rating and a $8.00 price objective on the stock. The consensus estimate for Personalis' current full-year earnings is ($1.40) per share. HC Wainwright also issued estimates for Personalis' Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.91) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.39) EPS and FY2028 earnings at ($0.05) EPS.

Other analysts also recently issued reports about the company. Needham & Company LLC reiterated a "buy" rating and set a $7.25 target price on shares of Personalis in a research report on Wednesday, January 8th. Lake Street Capital lifted their price objective on shares of Personalis from $7.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, January 8th.

Personalis Trading Down 2.6 %

Shares of PSNL stock traded down $0.14 on Wednesday, reaching $5.22. 586,741 shares of the company's stock were exchanged, compared to its average volume of 1,121,101. The company's fifty day simple moving average is $5.01 and its 200 day simple moving average is $4.80. Personalis has a 52 week low of $1.12 and a 52 week high of $7.20. The stock has a market capitalization of $368.79 million, a PE ratio of -3.11 and a beta of 1.75.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.31). The firm had revenue of $25.71 million during the quarter, compared to analysts' expectations of $20.67 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. During the same period last year, the company earned ($0.51) earnings per share.

Institutional Investors Weigh In On Personalis

Several hedge funds have recently made changes to their positions in PSNL. nVerses Capital LLC bought a new stake in shares of Personalis in the third quarter valued at about $40,000. SG Americas Securities LLC bought a new stake in shares of Personalis in the 4th quarter valued at about $63,000. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its position in shares of Personalis by 42.5% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company's stock worth $81,000 after purchasing an additional 4,504 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in shares of Personalis during the fourth quarter valued at approximately $87,000. Finally, International Assets Investment Management LLC increased its holdings in Personalis by 438.0% during the third quarter. International Assets Investment Management LLC now owns 20,982 shares of the company's stock valued at $113,000 after buying an additional 17,082 shares during the period. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.